Literature DB >> 1988007

High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects.

T Rönnemaa1, M Laakso, K Pyörälä, V Kallio, P Puukka.   

Abstract

The association between fasting plasma insulin level and coronary heart disease (CHD) was studied in 909 non-insulin-dependent diabetic (NIDDM) patients, aged 45-64 years, and in 1,373 nondiabetic control subjects. Both diabetic and nondiabetic subjects with various manifestations of CHD had higher plasma insulin levels than did subjects free of CHD. By plasma insulin quintiles formed according to values in nondiabetic subjects, the age-adjusted prevalence of CHD defined by symptoms and/or electrocardiographic changes in diabetic men was 48.2% in quintiles I + II (lowest), 54.8% in quintiles III + IV, and 65.7% in quintile V (highest) (p = 0.006). The respective prevalences in diabetic women were 53.5%, 59.1%, and 73.3% (p = 0.004); in nondiabetic men, 28.1%, 33.7%, and 43.3%, respectively (p = 0.016); and in nondiabetic women, 28.1%, 34.9%, and 44.3%, respectively (p = 0.007). An essentially similar association was observed between plasma insulin level and definite or possible myocardial infarction (MI). In diabetic subjects, a positive association between plasma insulin level and CHD manifestations was also found when insulin strata were formed using quintile cutoff points determined separately from diabetic subjects. The association between plasma insulin level and the prevalence of CHD or MI disappeared or was weaker, especially in men, when adjustment was made for body mass index, hypertension, and triglyceride or high density lipoprotein (HDL) cholesterol level. The association between high plasma insulin level and CHD was significant in diabetic subjects with a body mass index greater than 27 kg/m2 but not in those diabetics with a body mass index less than or equal to 27 kg/m2. A significant clustering of hypertension, high triglyceride values, and low HDL cholesterol levels was observed in diabetic subjects in the highest insulin quintiles. The results suggest that hyperinsulinemia is an indicator of CHD in both NIDDM patients and nondiabetic subjects. Hyperinsulinemia may be directly atherogenic, but it is more probable that hyperinsulinemia reflects insulin resistance, which may be a factor enhancing atherogenesis by causing adverse changes in many CHD risk factors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988007     DOI: 10.1161/01.atv.11.1.80

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  11 in total

1.  Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.

Authors:  M Möhlig; A Flöter; J Spranger; M O Weickert; T Schill; H W Schlösser; G Brabant; A F H Pfeiffer; J Selbig; C Schöfl
Journal:  Diabetologia       Date:  2006-09-14       Impact factor: 10.122

2.  Insulin treatment, NIDDM and atherosclerosis.

Authors:  S L Shumak
Journal:  CMAJ       Date:  1991-07-15       Impact factor: 8.262

Review 3.  Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice.

Authors:  S Vijan; D L Stevens; W H Herman; M M Funnell; C J Standiford
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

4.  Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.

Authors:  Hakuei Yamashita; Hiroo Yoda; Noriomi Kuroki; Michiko Kuwabara; Yuji Odagaki; Tetsushi Kazawa; Ryoichi Toyoshima; Taeko Maruki
Journal:  Psychopharmacology (Berl)       Date:  2010-09-04       Impact factor: 4.530

5.  Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study.

Authors:  J W Yarnell; P M Sweetnam; V Marks; J D Teale; C H Bolton
Journal:  Br Heart J       Date:  1994-03

6.  Evidence of higher insulin resistance in NIDDM patients with ischaemic heart disease.

Authors:  S Inchiostro; G Bertoli; G Zanette; V Donadon
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

7.  Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Authors:  Anum Saeed; Wensheng Sun; Anandita Agarwala; Salim S Virani; Vijay Nambi; Josef Coresh; Elizabeth Selvin; Eric Boerwinkle; Peter H Jones; Christie M Ballantyne; Ron C Hoogeveen
Journal:  Atherosclerosis       Date:  2018-12-30       Impact factor: 5.162

Review 8.  Hormone replacement therapy and the cardiovascular system. Nonlipid effects.

Authors:  J C Stevenson; D Crook; I F Godsland; P Collins; M I Whitehead
Journal:  Drugs       Date:  1994       Impact factor: 9.546

9.  Insulin excess counteracts the effects of HDL on intracellular sterol accumulation in cultured human skin fibroblasts.

Authors:  R L Brazg; E L Bierman
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

10.  Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis.

Authors:  Young M Park; Sangeeta R Kashyap; Jennifer A Major; Roy L Silverstein
Journal:  Lab Invest       Date:  2012-04-23       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.